Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Infusions in Clinically Depressed ICU Patients
NCT05803551Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Ketamine Group with Placebo Group (2 arms). Primary endpoints: Change in depressive symptoms and Clinically significant improvement of depressive symptoms. Started Jul 2025; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05803551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803551.